{
    "header": {
      "subtitle": "Advanced Drug Modality",
      "title": "PROTAC Technology",
      "description": "Proteolysis targeting chimeras (PROTACs) represent a paradigm shift in drug development, offering unprecedented control over protein degradation through innovative bifunctional molecules.",
      "buttons": [
        { "label": "Research Papers", "icon": "Microscope", "className": "bg-white text-purple-700", "link": "/research" },
        { "label": "Design Studio", "icon": "PenTool", "className": "bg-purple-800/40 backdrop-blur-sm text-white", "link": "/studio" }
      ]
    },
    "tabs": [
      {
        "id": "overview",
        "label": "Overview",
        "content": {
          "text": "PROTAC (Proteolysis Targeting Chimera) technology harnesses the cell's natural protein disposal system to selectively eliminate disease-causing proteins. Unlike traditional inhibitors that only temporarily block protein function, PROTACs tag target proteins for complete degradation by the proteasome, offering a more durable therapeutic effect.",
          "features": [
            {
              "title": "Key Features",
              "points": [
                {
                  "title": "Targeted protein degradation",
                  "description": "Selectively eliminates disease-causing proteins with high specificity."
                },
                {
                  "title": "AI-driven design",
                  "description": "Leverages machine learning for optimal linker and ligand configurations."
                },
                {
                  "title": "Rapid optimization",
                  "description": "Streamlined workflow for efficient molecule refinement and testing."
                }
              ]
            },
            {
              "title": "Applications",
              "points": [
                {
                  "title": "Cancer therapy",
                  "description": "Targeting previously undruggable oncogenic proteins."
                },
                {
                  "title": "Neurodegenerative diseases",
                  "description": "Eliminating toxic protein aggregates in Alzheimer’s and Parkinson’s."
                },
                {
                  "title": "Inflammatory conditions",
                  "description": "Controlling inflammation through targeted cytokine regulation."
                }
              ]
            }
          ]
        }
      },
      {
        "id": "mechanism",
        "label": "Mechanism",
        "content": {
          "heading": "How PROTACs Work",
          "description": "PROTACs are bifunctional molecules consisting of three key components that work together to degrade target proteins:",
          "steps": [
            {
              "number": 1,
              "title": "Target Protein Binder",
              "description": "A ligand that specifically recognizes and binds to the disease-causing protein."
            },
            {
              "number": 2,
              "title": "Flexible Linker",
              "description": "A chemical connector designed to optimize the positioning of the two binding elements."
            },
            {
              "number": 3,
              "title": "E3 Ligase Recruiter",
              "description": "A moiety that engages with the cell's protein degradation machinery."
            }
          ],
          "detailedDescription": "Once the PROTAC binds both the target protein and the E3 ligase, it forms a ternary complex. This proximity triggers the E3 ligase to ubiquitinate the target protein, marking it for degradation by the proteasome. After degradation, the PROTAC is released intact and can repeat the process with another target protein molecule."
        }
      },
      {
        "id": "benefits",
        "label": "Benefits",
        "content": {
          "heading": "Benefits Over Traditional Approaches",
          "benefits": [
            {
              "title": "Event-driven vs. Occupancy-driven",
              "description": "Triggers a degradation event rather than simply occupying a binding site, resulting in more complete protein elimination."
            },
            {
              "title": "Catalytic Mode of Action",
              "description": "A single PROTAC molecule can degrade multiple target proteins, enabling efficacy at lower dosages."
            },
            {
              "title": "Access to Undruggable Targets",
              "description": "Can target proteins that lack traditional drug-binding pockets, expanding the range of addressable disease targets."
            },
            {
              "title": "Enhanced Selectivity",
              "description": "The requirement for ternary complex formation adds an additional layer of selectivity, potentially reducing off-target effects."
            }
          ]
        }
      },
      {
        "id": "applications",
        "label": "Applications",
        "content": {
          "heading": "Therapeutic Applications",
          "sections": [
            {
              "title": "Oncology",
              "description": "PROTACs are being developed to target oncogenic proteins previously considered undruggable, including:",
              "items": [
                {
                  "title": "KRAS Mutants",
                  "description": "Targeting previously undruggable KRAS mutations found in pancreatic, colorectal, and lung cancers."
                },
                {
                  "title": "MYC Amplification",
                  "description": "Degrading the transcription factor MYC, which drives growth in multiple cancer types."
                }
              ]
            },
            {
              "title": "Neuroscience",
              "description": "PROTAC technology shows promise for neurodegenerative diseases characterized by protein aggregation:",
              "items": [
                {
                  "title": "Tau Protein",
                  "description": "Targeting tau tangles in Alzheimer’s disease and other tauopathies."
                },
                {
                  "title": "α-Synuclein",
                  "description": "Eliminating pathological α-synuclein in Parkinson’s disease."
                }
              ]
            }
          ]
        }
      }
    ]
  }
  